Effect of ultrapulse carbon dioxide laser combined with photodynamic therapy on facial angiofibroma in tuberous sclerosis complex

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200055795

Enrollment

Unknown

Registered

2022-01-20

Start date

2022-02-01

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tuberous sclerosis complex

Interventions

Treatment Group:ultrapulse carbon dioxide laser combined with photodynamic therapy

Eligibility

Sex/Gender

All

Age

6 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.Aged 6-60 years. 2.Patients diagnosed with tuberous sclerosis complex with angiofibroma lesions on the face. 3.Patients obtained informed consent.

Exclusion criteria

Exclusion criteria: 1.Patients suffering from serious systemic diseases of heart, brain, liver, kidney and blood, autoimmune diseases, chronic serious infections and other serious diseases. 2.Allergic to compound lidocaine cream or components in Aminolevulinic Acid Hydrochloride Topical Powder. 3.Those with scar constitution assessed by dermatologists. 4.Other reasons that the researcher considers not suitable for inclusion.

Design outcomes

Primary

Measure	Time frame
therapeutic effect;	—

Secondary

Measure	Time frame
Erythema area and severity;surface area of skin lesion;quantity of skin lesion;	—

Countries

China

Contacts

Public ContactGuoqiang Zhang

The First Hospital of Hebei Medical University

zgq810328@sina.com+8618633888122

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026